Thyroid disease affects approximately 200 million people globally, with Canada experiencing a particularly high incidence. According to the Thyroid Foundation of Canada, 1 in 10 Canadians suffers from a thyroid condition. In Europe, thyroid disease is one of the most common endocrine disorders, affecting millions of patients, with as many as 50% of cases remaining undiagnosed. Addressing this critical diagnostic gap, Nanospeed Diagnostics Inc. (Alberta) partnered with Microfluidic ChipShop GmbH (Germany) to develop an innovative solution.

Advanced Micro- and Nanotechnology-Enabled Point-of-Care Test Platforms

Nanospeed Diagnostics and Microfluidic ChipShop embarked on a mission to create a point-of-care test platform that provides quick and accurate access to essential personal health information. Their proprietary Diagnostic Test Kits, branded as Test4TTM, enable patients and health practitioners to perform thyroid profiling, including analysis of thyroid hormone levels, antibiotic levels, vitamin deficiency/sufficiency, and mineral levels, within minutes. This low-cost, disposable Lab on a Chip device ensures cost-effective testing, making quantitative analysis accessible to a broad population for a wide range of applications.

Positive Outcomes for Nanospeed Diagnostics

The collaboration, supported by the Alberta-Europe Technology Collaboration Fund—developed by Alberta’s Ministry of Jobs, Economy, and Innovation and delivered by the European-Canadian Centre for Innovation and Research—yielded significant benefits:

• Filing of two new patents
• Hiring of two new employees
• Significant revenue increase
• Ongoing collaboration with the German partner

Nanospeed Diagnostics Inc. and Microfluidic ChipShop GmbH’s successful partnership not only advanced thyroid diagnostics but also demonstrated the power of international cooperation in driving innovation and improving global health outcomes.